Ask AI
ProCE Banner Series

CNS 2026: H3 K27–Altered Diffuse Midline Glioma From Biopsy to Treatment: Neurosurgical Decisions in the Era of Molecularly Directed Therapy

H3 K27–altered diffuse midline glioma presents complex neurosurgical decisions because obtaining tissue can influence molecular diagnosis, treatment eligibility, and clinical trial access while requiring careful consideration of procedural risk and limited specimen availability. This program explores practical approaches to biopsy decision-making, tissue acquisition and molecular confirmation, and the treatment implications of confirmed H3 K27M–mutant disease, including current evidence for dordaviprone, along with how management of neurologic complications and timely multidisciplinary referral can support treatment and investigational options across the disease course.

Who Should Attend

This activity is intended for neurosurgeons, pediatric neurosurgeons, neurosurgical oncologists, neurosurgical fellows, and residents who evaluate or manage patients with diffuse midline glioma.

All Events

CNS 2026: H3 K27–Altered Diffuse Midline Glioma From Biopsy to Treatment: Neurosurgical Decisions in the Era of Molecularly Directed Therapy

Upcoming Events

November

03

2026

12:20 PM - 1:50 PM Eastern Time (ET)

In-person

Walter E. Washington Convention Center, 801 Allen Y. Lew Place NW, Washington, DC, District of Columbia 20001

Topics

Diffuse Midline Glioma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and confidence in obtaining a precise molecular diagnosis of H3 K27-altered DMG, integrating neurosurgical decision-making with current systemic treatment, and coordinating timely referral for multidisciplinary care.

Target Audience
This activity is intended for neurosurgeons, pediatric neurosurgeons, neurosurgical oncologists, neurosurgical fellows, and residents who evaluate or manage patients with diffuse midline glioma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Determine when stereotactic biopsy is likely to meaningfully alter diagnosis, treatment eligibility, or clinical trial access in patients with suspected DMG, considering tumor location, procedural risk, neurologic status, and alternatives to tissue acquisition

  • Apply neurosurgical tissue-acquisition and specimen-stewardship strategies that support integrated diagnosis through coordinated use of H3 K27M IHC, H3K27me3 assessment, sequencing, and broader molecular testing, while recognizing the adjunctive role and current limitations of CSF-tDNA

  • Evaluate current evidence for systemic therapy in progressive H3 K27M-mutant DMG, including dordaviprone efficacy, safety, regulatory status, evidence limitations, and ongoing Phase III evidence generation, distinguishing approved use in progressive disease following prior therapy from investigational post-radiotherapy use in newly diagnosed disease

  • Coordinate neurosurgical management across the DMG continuum, including hydrocephalus and neurologic deterioration, consideration of repeat tissue or CSF acquisition, and timely referral for systemic, cellular, and locoregional clinical trials

Accreditation

This activity is not certified for CME/CE credit.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191